Radiotherapy in Small Cell Carcinoma of the Uterine Cervix .
- Author:
Eun Ji CHUNG
1
;
Yong Hee LEE
;
Gwi Eon KIM
;
Chang Ok SUH
Author Information
1. Department of Radiation Oncology, Yonsei Cancer Center Yonsei University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Small cell carcinoma;
Neuroendocrine tumors;
Cervical carcinoma;
Radiotherapy;
Chemotherapy
- MeSH:
Biopsy;
Carcinoma, Neuroendocrine;
Carcinoma, Small Cell*;
Carcinoma, Squamous Cell;
Cervix Uteri*;
Coloring Agents;
Disease-Free Survival;
Drug Therapy;
Female;
Humans;
Lymph Nodes;
Middle Aged;
Neoplasm Metastasis;
Neuroendocrine Tumors;
Phosphopyruvate Hydratase;
Radiation Oncology;
Radiotherapy*;
Retrospective Studies;
Synaptophysin;
Tomography, X-Ray Computed
- From:Journal of the Korean Society for Therapeutic Radiology
1997;15(4):369-378
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: This study was performed to identify the histopathologic feature by the reevaluation of the pathologic specimen of the cervical tumors and to evaluate the clinical findings and the treatment results of the patients with small cell carcinoma of the cervix treated by radiotherapy. MATERIALS AND METHODS: 2890 patients with cervical carcinoma received radiotherapy at the Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine between October 1981 and April 1995. Of the 2890 patients in this data base, sixty were found to have small cell carcinomas (2.08%). Among them thirty six patients were transferred from other hospitals, the biopsy specimens of those patients were not available. So we could review the slides of the other twenty four patients who were diagnosed at our hospital. Twenty four patients with small cell carcinoma of the cervix were analyzed retrospectively based on the assessment of H & E staining and other four immunohistochemical stains for neuroendocrine differentiation (neuron specific enolase, chromogranin, synaptophysin and Grimelius stain). And we also evaluate the patients and tumor characteristics, response to radiation, patterns of failures, 5 year overall and disease free survival rates. RESULTS: Thirteen tumors were neuroendocrine carcinomas (13/24=54.2%) and eleven tumors were squamous carcinomas, small cell type (11/24= 47.8%) based on the assessment of H & E staining and other four neuroendocrine marker studies. So we classified the patients two groups as neuroendocrine carcinoma and small cell type of squamous carcinoma. Among the 13 neuroendocrine carcinomas, five were well to moderately differentiated tumors and the other eight were poorly differentiated or undifferentiated ones. The median age was 54 years old (range 23-79 years). Eight patients had FIGO stage IB disease, 12 had stage II, 3 had stage III and one had stage IV disease. Pelvic lymph node metastases were found in five patients(20.8%), three of them were diagnosed by surgical histologic examination and the other two were diagnosed by CT scan. There was no difference between two histopathologic groups in terms of patients and tumor characteristics, response to radiation, 5 year overall and disease free survival rates. However the distant metastases rate was higher in neuroendocrine carcinoma patients (6/13:46.2%) than in small cell type of squamous carcinoma patients (2/11:18.2%), but there was no statistically significant difference because of the small number of patients (P>0.05). CONCLUSION: More than half of the small cell carcinoma of the cervix patients were neuroendocrine carcinoma (13/24 : 54.1%) by reevaluation of the biopsy specimen of the cervical tumors. The tendency of distant metastases of the neuroendocrine carcinoma was greater than those of the small cell type of squamous carcinoma (46.2% vs. 18.2%). But there were no differences in the patients and tumor characteristics and other clinical treatment results in both groups. These data suggest that radical local treatment such as radiotherapy or radical surgery combined with combination systemic cytotoxic chemotherapy might provide these patients with the best chance for cure.
